Under the Paperwork Reduction Act of 1995, no persons are required to respon

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10596819				
iling Date		2006-06-26				
First Named Inventor Mitsu		uaki OSHIMA				
Art Unit		TBA				
Examiner Name TBA						
Homou Docket Number		49288 3100				

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number				Name of Patentee or Applicant Relev			ges,Columns,Lines where levant Passages or Relevant ures Appear		
	1										
If you wis	h to a	l dd additional U.S. Pater	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of sited Document		Releva		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	74
	1	11-015035	JP			1999-01-22	Nikon Corp				
	2	2001-346093	JP			2001-12-14	Matsushita Electric Co Ltd.	Ind			
	3	2002-027326	JP			2002-01-25	Minolta Co Ltd				

	4	2002-300460	JP		2002-10-11	Minolta Co Ltd			
	5	WO98/41818	wo		1998-09-24	Hitachi Ltd			
	6	11-134481	JP		1999-05-21	Canon Inc			
	7	2004-186901	JP		2004-07-02	Sany Corp			
	8	2004-239962	JP		2004-08-26	Nikon Corp			
	9	2004-354878	JP		2004-12-16	Minolta Co Ltd			
If you wisi	h to ac	d additional Foreign Pa				ease click the Add butto			
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials* Cite Initials* Cook, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dly andor country where published.									
	1 Copy of International Search Report dated 05/17/05								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Signa	ture				Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

	Application Number		10596819	
INFORMATION DIGGI COURT	Filing Date		2006-06-26	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Mitsu		iaki OSHIMA	
(Not for submission under 37 CFR 1.99)	Art Unit		TBA	
(Not for Submission ander or or it issay	Examiner Name TBA			
	Attorney Docket Numb	er	49288.3100	

See for Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. * Exister office in all research on documents, by the loss letter code (WIPO) Standard 51.3. * *Projectioned person of the patient obscurred. The patient obscurred is because the search received the patient obscurred. ** More of document by the appropriate symbols as indicated on the document will will be appropriate symbols as indicated on the document will be appropriate symbols as indicated on the document will be appropriate symbols as an extension as attacked.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596819			
Filing Date		2006-06-26			
First Named Inventor	Mitsu	aki OSHIMA			
Art Unit		TBA			
Examiner Name	TBA				
Attorney Docket Number		49288.3100			

CERTIFICATION STATEMENT

Please see	37	CFR :	1 97	and	1.98	to make	the	appropriate	selection(s)	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 137(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e)(s).

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Howard I Sobelman/	Date (YYYY-MM-DD)	2006-07-12
Name/Print	Howard I Sobelman	Registration Number	39.038

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.